ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Archives for December 2018

Dr. Fred R. Hirsch Departs IASLC CEO Role, Joins Mount Sinai Hospital

on: December 13, 2018In: Names & News
Dr. Fred R. Hirsch Departs IASLC CEO Role, Joins Mount Sinai Hospital

Posted: December 2018 Fred R. Hirsch, MD, resigned from his position of IASLC CEO at the end of October and has joined Mount Sinai Hospital in New York City as […] Read more


Prophylactic Cranial Irradiation in Locally Advanced NSCLC Falls Flat

on: December 12, 2018In: Radiation Oncology
Prophylactic Cranial Irradiation in Locally Advanced NSCLC Falls Flat

By John Armstrong, MD, FRCPI, DABR, FFRRCSI Posted: December 2018 RTOG 0214, a phase III randomized trial, is the biggest trial to date testing prophylactic cranial irradiation (PCI) in locally […] Read more

FDA Approval Processes in the Era of Targeted Therapies: A Conversation with Dr. Richard Pazdur

on: December 12, 2018In: Regulatory Agency Perspective
FDA Approval Processes in the Era of Targeted Therapies: A Conversation with Dr. Richard Pazdur

Posted: December 2018 Richard Pazdur, MD, is director of the U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence. Below, he discusses the current status of and future directions […] Read more

Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou

on: December 12, 2018In: Systemic, Targeted, & Immune Therapies
Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou

Posted: December 2018 In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical Oncology at the University of […] Read more

The Future Is Now: Pathology Is Going Digital

on: December 12, 2018In: Diagnostic Oncology
The Future Is Now: Pathology Is Going Digital

By Sanja Dacic, MD, PhD, and Douglas J. Hartman, MD Posted: December 2018 The pathology community initially showed resistance to digital pathology implementation in routine practice mostly because of pathologists’ […] Read more

Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to Date

on: December 12, 2018In: Systemic, Targeted, & Immune Therapies
Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in
            Activity to Date

By Ross Soo, MB BS, PhD, FRACP Posted: December 2018 The treatment of patients with advanced NSCLC harbouring an actionable oncogene with tyrosine kinase inhibitors (TKIs) directed at its oncogenic […] Read more

The State of Lung Cancer in Egypt: Progress Is at Hand

on: December 12, 2018In: Global Initiatives
The State of Lung Cancer in Egypt: Progress Is at Hand

By C.A.I.R.O Journal Club Executive Board Posted: December 2018 Egypt faced major turmoil in 2011, with subsequent dramatic political changes and a rapidly developing economic crises that, within a few […] Read more

Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC

on: December 12, 2018In: Systemic, Targeted, & Immune Therapies
Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC

By Mariano Provencio-Pulla, MD, PhD Posted: December 2018 Patients with stage IIIA NSCLC with clinically evident N2 nodal spread have an overall 5-year survival rate of only 10% to 15%. […] Read more

NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors

on: December 12, 2018In: Regulatory Agency Perspective
NCI Corner: Racial Differences in the Transcriptomes of Lung Tumors

Posted: December 2018 Investigators at the National Cancer Institute (NCI) compared the transcriptional profiles of lung cancers from African American patients to those from white patients and identified molecular differences […] Read more

Scientific Highlights from the IASLC Latin America Conference on Lung Cancer

on: December 12, 2018In: Meeting News
Scientific Highlights from the IASLC Latin America Conference on Lung Cancer

By Edgardo S. Santos Castillero, MD, FACP Posted: December 2018 Five abstracts were presented at the Presidential Symposium of the 2018 IASLC Latin America Conference on Lung Cancer, held in […] Read more

12

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy